Compare Charles River Laboratories Intl. Inc (CRL) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs MGM Resorts International — how do they compare? Charles River Laboratories Intl. Inc trades at $302.66 (market cap $14.23B), while MGM Resorts International trades at $29.83 (market cap $7.55B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and MGM Resorts International for 91 Days on average.
| CRL | MGM | |
|---|---|---|
Market Cap | $14.23B | $7.55B |
Volume | 1,176,885 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $50.69 |
52-Week Low | $149.93 | $30.00 |
Typical Hold Time | 33 Days | 91 Days |
Enterprise Value | $17.06B | $34.85B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
MGM Resorts International (MGM) trades at $30.00, down 1.77% on the day and facing bearish technical momentum despite recent earnings beats. The company shows mixed fundamentals with revenue growth to $17.54B in 2025 but declining net margins to 1.17%. Recent market sentiment has been negatively impacted by the collapse of Barry Diller's $48.30 per share acquisition offer, though MGM is now exploring a potential bid for Diller's People Inc. Analyst consensus remains bullish with a $48.75 price target representing significant upside potential.
The stock presents a compelling value opportunity with attractive valuation metrics (P/E 18.19, P/S 0.45) and strong analyst support, but faces near-term headwinds from deal uncertainty and bearish technical signals. Key risks include execution challenges in potential M&A activity and ongoing margin pressure in the competitive gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
